Search

Zhimin Zhimin Lu

from Houston, TX
Age ~59
Get Report
Also known as:
Zhi Min Lu, Shimin Lu Wang, Lu Zhimin, Lu Zimin, N Lu
Phone and address:
3023 Conway St, Houston, TX 77025
Related to:
Su U Wang, 66Hongxing X LuJenny LuSu ZhijianZhijian Su, 34
Connected to:
Abigail I Lu, 32Aiping Lu, 54Allen C Lu, 46Anjian Lu, 84Anna G Lu, 67Anne B Lu, 72Arnold W Lu, 49Ava Lu, 36Ay K Lu, 54Barbara T Lu, 74

Zhimin Lu Phones & Addresses

  • 3023 Conway St, Houston, TX 77025
  • 8181 Fannin St, Houston, TX 77054
  • 11406 Enclave Lake Ln, Pearland, TX 77584 (713) 436-3838
  • San Diego, CA
  • Flushing, NY
  • 11406 Enclave Lake Ln, Pearland, TX 77584

Business Records

Name / Title
Company / Classification
Phones & Addresses
Zhimin Lu
SIGNALWAY BIOTECHNOLOGY LLC
Games, Toys, Childrens Vehicles, Nec
11406 Enclave Lk Ln, Pearland, TX 77584
Zhimin Lu
Officer
SIGNALWAY ANTIBODY, INC
Direct Retail Sales
11406 Enclave Lk Ln, Pearland, TX 77584
(713) 436-0887

Publications

Us Patents

Cancer Treatment With Gã¶6976 And Its Related Compounds

View page
US Patent:
6696478, Feb 24, 2004
Filed:
Jul 24, 2001
Appl. No.:
09/912758
Inventors:
Zhimin Lu - San Diego CA, 92126
Keming Wang - Suzhou, 215002, CN
International Classification:
A61K 3140
US Classification:
514410
Abstract:
A chemotheraputic cancer treatment in which GÃ6976 or a compound chemically similar to GÃ6976 is administered to a mammal for the treatment of the cancer. The chemical compound is targeted to PKC activity. Experiments have shown GÃ6976 and similar compounds to be effective for the treatment of breast cancer, leukemia, lung cancer, bone cancer, skin cancer, prostate cancer, liver cancer, brain tumor, cervical cancer, and cancers located in the digestive tract including gastric cancer and colorectal cancers. These treatments may be accomplished utilizing GÃ6976 and compounds similar to it alone or in combination with prior art chemotherapy agents or with radiation therapy. In a preferred embodiment GÃ6976 is used for the treatment of cancer as a preventative drug by preventing cancer cell formation.

Cancer Treatment With Compounds Inhibiting Pkc Alpha

View page
US Patent:
20060009492, Jan 12, 2006
Filed:
Jul 7, 2005
Appl. No.:
11/175315
Inventors:
Zhimin Lu - Pearland TX, US
International Classification:
A61K 31/445
A61K 31/454
US Classification:
514320000
Abstract:
A chemotherapeutic cancer treatment with Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 or chemical compounds with similar structures is administered to a mammal for the treatment of the cancer. The chemical compound is targeted to PKC α activity. Experiments indicate that Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 and similar compounds to be effective for the treatment of breast cancer, leukemia, lung cancer, skin cancer, prostate cancer, liver cancer, brain tumor, cervical cancer, and cancers located in the digestive tract including gastric cancer and colorectal cancers. These treatments may be accomplished utilizing Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 and chemical compounds with similar structures alone or in combination with prior art chemotherapy agents or with radiation therapy. In a preferred embodiment Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 chemical compounds with similar structures is used for the treatment of cancer as a preventative drug by preventing cancer cell formation.

Cancer Treatment With Compounds Inhibiting Pkc Alpha

View page
US Patent:
20080009511, Jan 10, 2008
Filed:
Sep 20, 2007
Appl. No.:
11/902334
Inventors:
Zhimin Lu - Pearland TX, US
International Classification:
A61K 31/4353
A61K 31/4015
A61P 35/00
A61P 35/02
US Classification:
514294000, 514410000, 514414000
Abstract:
A chemotherapeutic cancer treatment with Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 or chemical compounds with similar structures is administered to a mammal for the treatment of the cancer. The chemical compound is targeted to PKC α activity. Experiments indicate that Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 and similar compounds to be effective for the treatment of breast cancer, leukemia, lung cancer, skin cancer, prostate cancer, liver cancer, brain tumor, cervical cancer, and cancers located in the digestive tract including gastric cancer and colorectal cancers. These treatments may be accomplished utilizing Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 and chemical compounds with similar structures alone or in combination with prior art chemotherapy agents or with radiation therapy. In a preferred embodiment Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 chemical compounds with similar structures is used for the treatment of cancer as a preventative drug by preventing cancer cell formation.

Treatment Of Viral Disease And Cancer With Nf-Kappab Inhibitors

View page
US Patent:
20090082371, Mar 26, 2009
Filed:
Jun 19, 2006
Appl. No.:
11/922323
Inventors:
Zhimin Lu - Pearland TX, US
International Classification:
A61K 31/517
A61K 31/343
A61K 31/10
A61K 31/35
A61K 31/12
US Classification:
5142664, 514470, 514710, 514456, 514683
Abstract:
A method using quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, and 7-Methoxy-5,11,12-trihydroxy-coumestan is administered to a mammal for the treatment and prevention of viral diseases and cancers. The chemical compounds are targeted to inhibit NF-κB transcriptional activity. These treatments for viral diseases, especially for infection caused by HIV, and cancers may be accomplished utilizing quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, 7-Methoxy-5,11,12-trihydroxy-coumestan, and compounds similar to them alone or in combination with prior art other therapy.

Cancer Treatment With Go 6976

View page
US Patent:
63036460, Oct 16, 2001
Filed:
Aug 9, 1999
Appl. No.:
9/370190
Inventors:
Zhimin Lu - San Diego CA
Keming Wang - Suzhou, CN
International Classification:
A61K 3140
US Classification:
514410
Abstract:
A chemotheraputic cancer treatment in which Go6976 or one of its derivatives is administered to a mammal for the treatment of the cancer. The Go6976 or its derivative is directed to PKC. alpha. activity. Experiments have shown Go6976 to be effective for the treatment of breast cancer, leukemia, lung cancer, bone cancer and skin cancer. These treatments may be accomplished utilizing Go6976 or its derivatives alone or in combination with other prior art chemotherapy agents or in combination with radiation therapy. In a preferred embodiment Go6976 is used for the treatment of cancer as a preventative drug by preventing cancer cell formation.

The Protein Kinase Activity Of Phosphoglycerate Kinase 1 As A Target For Cancer Treatment And Diagnosis

View page
US Patent:
20180011102, Jan 11, 2018
Filed:
Jan 5, 2016
Appl. No.:
15/541501
Inventors:
- Austin TX, US
Zhimin LU - Pearland TX, US
International Classification:
G01N 33/574
A61K 45/06
A61K 31/713
G01N 33/50
Abstract:
Compositions and methods for characterizing cancer cells by determining a marker of PGK1 activity. For example, methods are provided for predicting a patient response to a PGK1 inhibitor, a MEK/ERK inhibitor, an EGFR inhibitor, or a PIN1 inhibitor therapy. Methods for treating patients with such therapies are likewise provided.
Control profile
Zhimin Zhimin Lu from Houston, TX, age ~59 Get Report